These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 38733885)
1. Development of novel N-aryl-2,4-bithiazole-2-amine-based CYP1B1 degraders for reversing drug resistance. Yao X; Mao J; Zhang H; Xiao Y; Wang Y; Liu H Eur J Med Chem; 2024 Jun; 272():116488. PubMed ID: 38733885 [TBL] [Abstract][Full Text] [Related]
2. Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin. Lin H; Hu B; He X; Mao J; Wang Y; Wang J; Zhang T; Zheng J; Peng Y; Zhang F Biochem Pharmacol; 2020 Jan; 171():113733. PubMed ID: 31783010 [TBL] [Abstract][Full Text] [Related]
3. Structure-Based Drug Design and Synthesis of Novel Mao J; Wang D; Xu P; Wang Y; Zhang H; Wang S; Xu F; Wang J; Zhang F J Med Chem; 2022 Dec; 65(24):16451-16480. PubMed ID: 36512763 [TBL] [Abstract][Full Text] [Related]
4. α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship. Chen P; Wang S; Cao C; Ye W; Wang M; Zhou C; Chen W; Zhang X; Zhang K; Zhou W Bioorg Chem; 2021 Nov; 116():105295. PubMed ID: 34455300 [TBL] [Abstract][Full Text] [Related]
5. Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification. Wang Y; He X; Li C; Ma Y; Xue W; Hu B; Wang J; Zhang T; Zhang F Eur J Med Chem; 2020 May; 193():112235. PubMed ID: 32203789 [TBL] [Abstract][Full Text] [Related]
6. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner. Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681 [TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation. Zhou L; Chen W; Cao C; Shi Y; Ye W; Hu J; Wang L; Zhou W Eur J Med Chem; 2020 Mar; 189():112028. PubMed ID: 31945665 [TBL] [Abstract][Full Text] [Related]
8. Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance. Sun N; Ren C; Kong Y; Zhong H; Chen J; Li Y; Zhang J; Zhou Y; Qiu X; Lin H; Song X; Yang X; Jiang B Eur J Med Chem; 2020 May; 193():112190. PubMed ID: 32179332 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and evaluation of N-hydroxypropenamides based on adamantane to overcome resistance in NSCLC. Bao X; Sun Y; Bao C; Zhang J; Zou S; Yang J; Wu C; Wang L; Chen G Bioorg Chem; 2019 May; 86():696-704. PubMed ID: 30831531 [TBL] [Abstract][Full Text] [Related]
10. Glycyrrhiza glabra extract and quercetin reverses cisplatin resistance in triple-negative MDA-MB-468 breast cancer cells via inhibition of cytochrome P450 1B1 enzyme. Sharma R; Gatchie L; Williams IS; Jain SK; Vishwakarma RA; Chaudhuri B; Bharate SB Bioorg Med Chem Lett; 2017 Dec; 27(24):5400-5403. PubMed ID: 29150398 [TBL] [Abstract][Full Text] [Related]
11. Design and Synthesis of New α-Naphthoflavones as Cytochrome P450 (CYP) 1B1 Inhibitors To Overcome Docetaxel-Resistance Associated with CYP1B1 Overexpression. Cui J; Meng Q; Zhang X; Cui Q; Zhou W; Li S J Med Chem; 2015 Apr; 58(8):3534-47. PubMed ID: 25799264 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of Anti-Metastatic Potential of the Combination of Fisetin with Paclitaxel on A549 Non-Small Cell Lung Cancer Cells. Klimaszewska-Wiśniewska A; Hałas-Wiśniewska M; Grzanka A; Grzanka D Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495431 [TBL] [Abstract][Full Text] [Related]
13. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe. Bai Z; Gao M; Zhang H; Guan Q; Xu J; Li Y; Qi H; Li Z; Zuo D; Zhang W; Wu Y Cancer Lett; 2017 Aug; 402():81-92. PubMed ID: 28576750 [TBL] [Abstract][Full Text] [Related]
14. Low dose HSP90 inhibition with AUY922 blunts rapid evolution of metastatic and drug resistant phenotypes induced by TGF-β and paclitaxel in A549 cells. Bacon NA; Larre I; Lawag AA; Merritt C; Smith M; Rosolen M; Sollars VE Biomed Pharmacother; 2020 Sep; 129():110434. PubMed ID: 32768937 [TBL] [Abstract][Full Text] [Related]
15. Repurposing of a monoamine oxidase A inhibitor‑heptamethine carbocyanine dye conjugate for paclitaxel‑resistant non‑small cell lung cancer. Yang XG; Li YY; Zhao DX; Cui W; Li H; Li XY; Li YX; Wang D Oncol Rep; 2021 Mar; 45(3):1306-1314. PubMed ID: 33650669 [TBL] [Abstract][Full Text] [Related]
16. RNAi targeting STMN alleviates the resistance to taxol and collectively contributes to down regulate the malignancy of NSCLC cells in vitro and in vivo. Long D; Yu T; Chen X; Liao Y; Lin X Cell Biol Toxicol; 2018 Feb; 34(1):7-21. PubMed ID: 28589243 [TBL] [Abstract][Full Text] [Related]
17. Daurinoline suppressed the migration and invasion of chemo-resistant human non-small cell lung cancer cells by reversing EMT and Notch-1 and sensitized the cells to Taxol. Li DD; Qin XC; Yang Y; Chu HX; Li RL; Ma LX; Ding HW; Zhao QC Environ Toxicol Pharmacol; 2019 Feb; 66():109-115. PubMed ID: 30641414 [TBL] [Abstract][Full Text] [Related]
18. PPARα agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPARα/AMPK/AKT/FoxO1 pathway. Wang MS; Han QS; Jia ZR; Chen CS; Qiao C; Liu QQ; Zhang YM; Wang KW; Wang J; Xiao K; Ding XS Acta Pharmacol Sin; 2022 Jan; 43(1):167-176. PubMed ID: 33772142 [TBL] [Abstract][Full Text] [Related]
19. The synthesis of 4,6-diaryl-2-pyridones and their bioactivation in CYP1 expressing breast cancer cells. Ruparelia KC; Lodhi S; Ankrett DN; Wilsher NE; Arroo RRJ; Potter GA; Beresford KJM Bioorg Med Chem Lett; 2019 Jun; 29(11):1403-1406. PubMed ID: 30935796 [TBL] [Abstract][Full Text] [Related]
20. NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway. Jiang P; Xu H; Xu C; Chen A; Chen L; Zhou M; Haq IU; Wu X; Mariyam Z; Feng Q Chem Biol Interact; 2018 Dec; 296():154-161. PubMed ID: 30291867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]